Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...

MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score(R) ...

Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...

本研究针对巴西乳腺癌辅助化疗可能过度使用的问题，通过决策树-马尔可夫模型评估Oncotype DX基因组测试的成本效益。结果 ...

REDWOOD CITY, Calif., Oct. 22, 2018 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from multiple studies of its Oncotype DX ® tests highlighting their value in optimizing ...

Genomic Health announced results of three new Oncotype DX studies demonstrating the test's cost-effectiveness within the German and Hungarian healthcare systems, and Israeli data showing the test's ...

Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.

New ASCO Recommendations Increase Proportion of Women Who Can Be Spared Chemotherapy Based on Landmark TAILORx and NSABP B-20 Randomized Clinical Trials Additional Secondary Analysis of TAILORx Trial ...